Newman, M.D., M.P.H., director of the Breasts Care Middle at the U-M In depth Cancer Center. Related StoriesScientists discover small molecule that can block development of BRCA-deficient cancers cellsMD Anderson research reveals why chemotherapy drugs not effective for most pancreatic malignancy patientsCornell biomedical engineers develop 'super organic killer cells' to eliminate tumor cells in lymph nodesThe scholarly study, published on the web in the journal Malignancy, looked at 581 African American females and 1,008 white women identified as having breast cancers at the Henry Ford Wellness System in Detroit, plus 75 African women diagnosed at the Komfo Anokye Teaching Medical center in Ghana.‘Pegsiticase has recently shown significant efficacy signals in gout individuals and we have the opportunity to build up a novel therapeutic approach with the goal of avoiding the inhibitory antibodies and various other complications of immunogenicity that have been a substantial barrier to the widespread usage of uricase-based drugs. With the mix of pegsiticase and SVP, we believe we are able to significantly improve treatment for individuals with refractory and tophaceous gout,’ stated Werner Cautreels, PhD, President and Chief Executive Officer of Selecta. ‘Working with 3SBio, we’ve the potential to fulfill a key medical want expressed by doctors – the first non-immunogenic uricase. 3SBio's strength of enzyme production combined with Selecta's proprietary antigen-specific tolerance platform can ensure fast improvement towards human proof of concept.